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Introduction
In light of large multicenter studies, the time limited
renal graft function remains one of the key problems of
current transplantology [1]. Despite the dropping preva-
lence of clinically manifest acute rejection and despite the
active approach to diagnostics and treatment of subclini-
cal rejection, adequate improvement in the long-term
graft survival has not been achieved [2].
The chronic nephrotoxic effects of calcineurin inhibi-
tors (CI) associated with the development of chronic
parenchymal changes play a major role in the pathogene-
sis of late dysfunction [3]. The effort to achieve maxi-
mum CI dose reduction and careful monitoring of its
serum levels are very important in the prevention of
the development of these irreversible changes. The
administration of CI, however, is complicated by the
much varied pharmacokinetics, narrow therapeutic range,
and individual sensitivity to toxic effects [4]. For these
reasons, CI serum levels often do not correlate with the
scope of kidney damage and the manifestation of toxicity
may be nonspeciﬁc, or the toxic changes may be, espe-
cially in the ﬁrst months after transplantation, clinically
silent. The impact of this subclinical toxicity on the pro-
gression of chronic graft changes is likely, yet available
data are limited [5].
The purposes of our prospective study were to evaluate
the prevalence of subclinical toxicity in repeated protocol
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Summary
The purpose of the prospective study was to determine the prevalence of sub-
clinical toxicity of calcineurin inhibitors (CI) in repeated protocol renal allo-
graft biopsies and to assess its impact on the development of chronic graft
changes. A total of 424 biopsies were conducted in a cohort of 158 patients; of
these biopsies, 158 were in the third week, 142 were in the third month and
124 were in the ﬁrst year after transplantation. Histological signs of toxicity
occurred in the third week in 33 (20.1%) patients, with persistence after CI
dose reduction in the third month in 27 (19.0%) and in the ﬁrst year in 23
(18.5%) patients. Of the toxic changes, 52% were clinically silent. At the end
of the one-year follow-up, both subclinical and clinically manifest toxicity
resulted in a similar progression of chronic changes quantiﬁed by Banff chro-
nicity score and they signiﬁcantly differed from the control group (P < 0.05).
Subclinical toxicity affects a signiﬁcant percentage of grafts; it occurs indepen-
dently of dosage, blood level and type of applied CI. It is associated with the
progression of chronic changes as early as in the ﬁrst year after transplantation
and represents an independent risk factor for chronic allograft damage. We
report here our clinical approach to toxicity.
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the ﬁrst year after the transplantation and to assess its
impact upon the development of chronic graft changes at
the end of the one-year monitoring. Concurrently, we
strove to determine whether there was any difference
between the two applied CI – cyclosporin A and tacroli-
mus – in terms of their ability to affect the development
of toxic and, subsequently, chronic changes.
Patients and methods
Study design
This was a prospective, nonrandomized, single-arm, one-
centre study which was conducted according to ICH/GCP
guidelines and supported by a grant and research project.
The trial was approved by the Local Ethics Committee
and all patients gave their written and dated informed
consent before inclusion in the study. In total, 424 proto-
col graft biopsies were conducted in a cohort of 158
patients with new transplants. The population consisted of
88 women and 70 men aged 18–73 years, with mean age
of 51.2 ± 13.1 years. All patients received a kidney from a
deceased donor; for six patients it was their second trans-
plantation and in one case, it was a third transplantation.
Individuals included in the study were treated by a triple
combination immunosuppressive therapy including cyclo-
sporin A or tacrolimus, the antimetabolite azathioprine or
the mycophenolate mofetil and prednison. In the induc-
tion therapy, we used mostly methylprednisolon (Day
0–500 mg i.v. perioperatively, Day 1–250 mg i.v.), as well
as anti-thymocyte globulin, and, where appropriate, anti-
IL2-R monoclonal antibody in recommended dosage. The
initial CI dose was administered 4 h before the operative
procedure, in patients indicated for treatment with cyclo-
sporin A it was 3 mg/kg, and 0.1 mg/kg for tacrolimus.
Further CI dosage was maintained with regard to the
levels and time from transplantation (Table 1). Where his-
tological signs of toxicity were seen, the dose was reduced
by 25–50% with a view to the initial CI level. Patients
receiving azathioprine or mycophenolate mofetil were kept
at the dosage of 1.5 mg/kg/day and 2 g/day, respectively,
with dose reduction upon the incidence of adverse events
or complications associated with this therapy. All patients
were given prednison in the dose of 30 mg from Day 2 to
day 14, 20 mg from Day 15 to Month 2 after the trans-
plantation, and then 15 mg from Month 3 to month 5
and 10 mg from Month 6 to month 12.
Protocol biopsies and histological evaluation
Biopsies were carried out in the third week, third month
and the ﬁrst year after the transplantation. A total of 158
biopsies were performed in the third week, 142 in the
third month and 124 in the ﬁrst year. The procedure was
conducted using the Magnum MG 1522 automatic biopsy
system and Magnum 14 G/13 cm biopsy needles. Two
samples were taken under ultrasound control from the
lower pole of the graft. The histological evaluation of the
biopsy specimen used the modiﬁed Banff 97 classiﬁcation
[6,7], performed by a single pathologist familiar with the
clinical progress. A sample containing at least seven
glomeruli and at least one artery was rated as adequate.
Following sampling, the tissue was preserved in 10% for-
malin, processed in a normal manner and embedded in
parafﬁn. Histological samples were processed to slices of
3–4 micron thickness and then stained with haematoxylin
eosin on three slides, using the Periodic Acid-Schiff
method on three slides and using Masson trichrome on
one slide. Immunohistochemical analysis using polyclonal
antibody was employed for the detection of C4d positivity
in peritubular and glomerular capillaries. A minimum of
12 slices from each sample were evaluated.
Isometric vacuolization of the tubular epithelium,
necrotic arteriole myocytes with early deposition of eosin-
ophilic globular material in arteriole walls, the presence
of ﬁbrinoid arteriole necrosis, and, eventually, thrombotic
microangiopathy with concurrent exclusion of acute
rejection as well as accelerated hypertension were consid-
ered manifestations of acute CI toxicity. Arteriole myo-
cytes vacuolization, a whirling myocytes pattern, tubular
microcalciﬁcations and arterial mucoid intimal thickening
were not classiﬁed as certain signs of toxicity on their
own, but merely in combination. The signs of chronic
toxicity were considered the striped cortical ﬁbrosis, tubu-
lar atrophy, nodular and circular arteriolohyalinosis and
hyperplasia of the juxtaglomerular apparatus. Focal global
Table 1. Target levels of calcineurin inhibitors in dependence on time
offset after transplantation.
Level CI (lg/l) Time offset after transplantation
CsA-C 0
a 250–350 Days 1–6
200–300 Days 7–30
150–200 Months 2–6
100–200 >6months
CsA-C 2
b 1300–1800 Month 1
1200–1600 Month 2
1000–1400 Month 3
900–1200 Months 4–6
700–1000 Months 7–12
FK-C 0
c 10–20 Days 1–14
10–15 Days 15–30
5–10 >30 days
CI, calcineurin inhibitor.
aCsA-C 0, trough level of cyclosporin A.
bCsA-C 2, 2-hour cyclosporin A post-dose level.
cFK-C 0, trough level of tacrolimus.
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brane reduplication and without podocyte hyperplasia
was classiﬁed as the sign supporting the diagnosis, as well
as tubular microcalciﬁcation. None of the above men-
tioned signs occurred as isolated in the samples.
Laboratory analysis
Immediately before each biopsy, laboratory parameters of
the transplanted kidney function were established – glo-
merular ﬁltration rate by Nankivell and serum creatinine
concentration by enzymatic method. A serum creatinine
level of 125 lmol/l was determined as the upper limit of
normal values (ULN). The function of the graft was con-
sidered stabilized in serum creatinine ﬂuctuations <10%
at least within two weeks prior to the protocol biopsy.
Cyclosporin A and tacrolimus levels were established as
fasting levels 12 h following prior application. In half of
patients taking cyclosporin A, they were established
also two hours following oral application of cyclosporin
A (C 2 level). The analytical method employed was
ﬂuorescence polarization immunoassay (FPIA ABBOTT
Laboratories).
Inclusion and exclusion criteria and BCS monitoring
Based on the results of graft function established through
the biopsies conducted in the third week after transplan-
tation, four groups were detached from the study popula-
tion to serve the object of our interest. Patients with
normal histological ﬁndings and stabilized graft function
were included in the comparison group (NORMAL). Sub-
jects with histological signs of CI toxicity, but normal and
stabilized graft function were placed in the subclinical
toxicity group (S-TOX). Those with histological evidence
of toxicity and an impaired graft function without any
other cause of dysfunction were included in the clinically
manifest toxicity group (M-TOX). Patients with histologi-
cal signs of toxicity, independent of the graft function,
were also evaluated (S+M-TOX group). The CI level was
not a criterion affecting the inclusion of the patient in
any of the monitored groups. Two CI patient subgroups
were deﬁned in each group – one with cyclosporin A
(CsA subgroup), and one with tacrolimus (FK subgroup).
The patients who had medical and technical contraindi-
cations and limitations for biopsy and who refused to sign
the informed consent form were not included in the study
or were subsequently withdrawn from the study. The same
procedure was applied to the identiﬁcation of an acute
rejection in any form (antibody or T-cell mediated, incl.
borderline rejection changes and subclinical acute rejec-
tion), recurrent and de novo glomerulonephritis, acute
pyelonephritis and CMV infection at the beginning and
thereafter at any time during the study, for the reason of
potential inﬂuence upon chronic damage progression. All
of the studied groups and subgroups were monitored for
the development of chronic changes (ci, ct, cg, cv) using
Banff chronicity score (BCS) in the course of the one-year
monitoring, and cross-comparisons of a number of other
donor, donor kidney and recipient parameters were car-
ried out. Chronic changes identiﬁed in the third week
were, in otherwise uncomplicated post-transplantation
course, considered as a transfer from donor. The S-TOX
and M-TOX groups were separately evaluated for potential
persistence of toxic signs in subsequent biopsy in relation
to the previous CI dose reduction.
Statistical analysis
For the statistical analysis of the results the spss for Win-
dows, version 15.0 software (SPSS Inc., Chicago, IL, USA)
was used. Quantitative elements in this work were
described using the statistics average ± SD, category ele-
ments using frequency distribution. Chi-square test or
Fisher’s exact test (suitable for low frequencies) was used
for the comparison of individual groups in categorical
elements. In terms of quantitative elements, the groups
were compared using analysis of variance and LSD post
hoc tests. Group comparisons employed, depending on
the nature of data, either nonparametric Mann–Whitney
U-test (in the case of abnormal distribution of values or
presence of extreme values in the data) or two-tailed
t-test. Test results were labelled as signiﬁcant where the
level of statistical signiﬁcance P < 0.05 was achieved.
Results
Prevalence and persistence of subclinical and clinically
manifest toxicity
Table 2 documents four groups isolated from the study
population for the next evaluation in the third week and
the degree of persistence of these baseline parameters in
the course of the one-year monitoring. In the third week, a
surprisingly low percentage of normal histological ﬁndings
were seen – only in 30 patients (19.0%). The identiﬁcation
of CI toxicity, on the contrary, was rather high – clinically
manifest in 16 patients (10.1%) and subclinical in 17
patients (10.8%), as well as the high persistence of toxic
changes in the course of the one-year monitoring in both
toxicity groups, regardless of the repeated reductions in the
CI dose. In a maximum of 12% of patients with histologi-
cal evidence of toxicity, the elevation of serum creatinine
was seen at the same time (Table 3). Patients who no
longer complied with the required criteria and in whom
no further biopsy had been performed were excluded from
the studied groups in the third month and in the ﬁrst year.
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continued to participate in the study in the third month;
12 in the CyA subgroup and nine in the FK subgroup, and
at the end of the one-year monitoring, 14 patients were
evaluated in this group; eight in the CyA subgroup and six
in the FK subgroup. In the S-TOX and M-TOX groups, 14
and 13 patients respectively continued to participate in the
study in the third month (nine in the CyA subgroup and
ﬁve in the FK subgroup and seven in the CyA subgroup
and six in the FK subgroup), and at the end of the one-year
monitoring, the number of evaluated patients was 12 and
11 respectively (seven in the CyA subgroup and ﬁve in the
FK subgroup; and six in the CyA subgroup and ﬁve in the
FK subgroup). Of the total number of seven patients with
re-transplantations who had a biopsy in the third week,
only three patients continued to participate in the study in
the third month. These were evenly distributed across
studied groups and the impact of re-transplantation upon
the development of monitored parameters could thus be
disregarded.
BCS and serum creatinine evaluation
The assessment of the impact of persisting subclinical tox-
icity on the progression of chronic graft changes employed
a comparison of the BCS development in this group with
ﬁndings in the NORMAL and M-TOX groups. Earlier,
groups had been compared for a number of baseline
donor and recipient parameters, kidney graft parameters
and other factors potentially inﬂuencing the development
of chronic changes (Table 4). Similar comparison was
then conducted again in the third month and the ﬁrst year
after transplantation (data not presented), always along
with the protocol biopsy. No signiﬁcant difference among
groups was found in the monitored parameters and no
other immunopathogenic conditions resulting in systemic
impairment have occurred in the patients in the course of
the study. Hence, the progression of chronic changes
could be assessed in relation to the presence or absence of
toxicity. Figure 1 documents the development of the BCS
of evaluated groups. In the NORMAL group, the increase
was only moderate and did not reach statistical signiﬁ-
cance at the end of the one-year monitoring. In the
M-TOX group, a signiﬁcant increase in the BCS was iden-
tiﬁed as early as from the third week to the third month
after transplantation, and a further signiﬁcant increase
occurred from the third month to the ﬁrst year after
transplantation. Surprisingly, the similar progression of
chronic changes was also seen in patients with subclinical
toxicity. Moreover, BCS values in this group did not differ
signiﬁcantly from the values found in the M-TOX group.
Figure 2 shows the development of serum creatinine
levels in individual groups. In the NORMAL and S-TOX
groups, no signiﬁcant change was seen in the course of
Table 2. Four detached groups from the study population and rate of persistency of these baseline histological ﬁndings during one year follow-
up.
Group
3rd week 3rd month 1st year
n (%) Creatinine (lmol/l) mean ± SD n (%) Creatinine (lmol/l) mean ± SD n (%) Creatinine (lmol/l) mean ± SD
NORMAL 30 (19.0) 102.5 ± 18.9 21 (14.8) 111.8 ± 21.3 14 (11.3) 105.0 ± 15.7
S-TOX 17 (10.8) 98.6 ± 15.1 14 (9.9) 101.4 ± 14.4 12 (9.7) 103.0 ± 13.6
M-TOX 16 (10.1) 207.8 ± 107.2 13 (9.2) 161.8 ± 29.4 11 (8.9) 147.7 ± 14.7
S+M-TOX 33 (20.9) 151.6 ± 92.6 27 (19.0) 130.5 ± 38.1 23 (18.5) 124.4 ± 26.7
Data are mean ± standard deviation (SD) or number (%).
NORMAL, normal histological ﬁnding; S-TOX, subclinical toxicity of calcineurin inhibitors; M-TOX, manifest toxicity of calcineurin inhibitors; S+M-
TOX, composite group with subclinical and manifest toxicity.
Table 3. Graft function in relation to
level of calcineurin inhibitor at patients
with subclinical and manifest toxicity. S+M-TOX group
3rd week n (%) 3rd month n (%) 1st year n (%)
33 (20.9) 27 (19.0) 23 (18.5)
Elevated creatinine 16 (48.5) 13 (48.1) 11 (47.8)
Elevated CI 11 (33.3) 7 (25.9) 3 (13.0)
CI and creatinine elevated 4 (12.1) 3 (11.1) 1 (4.3)
Creatinine in a normal range 17 (51.5) 14 (51.9) 12 (52.2)
CI in a normal range 22 (66.7) 20 (74.1) 20 (87.0)
CI and creatinine in a normal range 10 (30.3) 10 (37.0) 10 (43.5)
Data are number (%).
S+M-TOX group, composite group with subclinical and manifest toxicity; CI, trough level of calci-
neurin inhibitor.
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nent drop in creatinine was observed, probably as a
response to the repeatedly reduced CI doses; the drop
reached its maximum in the period from the third week
to the third month, but was not statistically signiﬁcant.
Changes in the glomerular ﬁltration rate were not signiﬁ-
cant either.
Cyclosporin A and tacrolimus toxicity
The comparisons of cyclosporin A and tacrolimus in
terms of their toxic potential and ability to affect the
progression of chronic changes are documented in
Table 4. Baseline characteristics and others monitored parameters of
the initial cohort (n = 158).
Characteristics of the donor
Age (years) (mean ± SD) 47.6 ± 19.3
Gender (Male/Female) 57.6/42.4
Race (W/B/A/H) 100/0/0/0
Deceased/living 100/0
Cause of death (T/K/I/H) 41.2/54.4/1.9/2.5
Number of mismatches – HLA-A (0/1/2) 8.2/54.4/37.4
– HLA-B (0/1/2) 5.3/45.6/49.1
– HLA-DR (0/1/2) 15.8/58.2/26.0
HLA-A, B, DR mismatch (mean ± SD) 3.7 ± 1.0
Blood group (A/O/B/AB) 39.2/42.4/14.6/3.8
Vasopressor administration (Y/N) 34/66
Diuresis (litres) (mean ± SD) 2.59 ± 2.34
Preservation solution (C/EC/UW/CU) 0/5.7/17.1/77.2
Serum creatinine (mean ± SD) 97.62 ± 41.54
CMV IgG (P/N)
a 64.6/35.4
CMV IgM (P/N) 7.6/92.4
Characteristics of the recipient
Age (years) (mean ± SD) 51.2 ± 13.1
Gender (Male/Female) 44.3/55.7
Race (W/B/A/H) 100/0/0/0
Re-transplantation (Y/N) 4.4/95.6
Recipient diagnosis (GN/TIN/DM/PCKD/AS/T) 40.5/30.4/7.6/21.5/0
Waiting time (months) (mean ± SD) 23.14 ± 22.55
Residual diuresis (litres) (mean ± SD) 0.88 ± 0.81
Dry weight (kg) (mean ± SD) 72.37 ± 14.16
Blood group (A/O/B/AB) 40.5/38.6/15.2/5.7
HLA compatibility index (mean ± SD) 12.98 ± 5.68
Last PRA 6.8 ± 17.4
Maximal PRA 12.27 ± 25.98
Onset of graft function (I/DGF/NF) 75.9/24.1/0
Induction with MP, ATG, anti-IL2-R 85.5/6.9/7.6
Maintenance immunosuppression
CS (Y/N) 100/0
Mean daily dose ± SD (mg) 19.0 ± 3.4
CsA (Y/N) 65.8/34.2
Trough level of CsA C 0
b ±S D( lg/l) 278 ± 89.5
2-hour CsA post-dose level C 2
c±S D( lg/l)1515 ± 246
FK (Y/N) 34.2/65.8
Trough level of FK C 0
d ±S D( lg/l) 14.5 ± 6.4
AZA (Y/N) 38.6/61.4
Mean daily dose ± SD (mg/kg) 1.68 ± 0.36
MMF (Y/N) 61.4/38.6
Mean daily dose ± SD (mg) 1659 ± 493
Systolic BP (mean ± SD) 136.17 ± 15.41
Ca blocker/statin/ACEI or ATRA therapy 70.9/84.8/54.4
IGT-DM (Y/N) 16.9/83.1
Characteristics of the graft
Number of arteries (1/2/3) 84.2/14.5/1.3
Number of veins (1/2/3) 90.5/8.9/0.6
Number of urethers (1/2/3) 99.4/0.6/0
Table 4. Continued
Cold-ischaemia time (hours) (mean ± SD) 14.67 ± 5.43
BCS-T (mean ± SD) 0.63 ± 0.70
BSA (mean ± SD) 0.46 ± 0.52
Data are mean ± standard deviation (SD) or number (%).
W/B/A/H, White/Black/Asian/Hispanic; T/K/I/H, craniotrauma/spontane-
ous bleeding into the brain/intoxication/hypoxia; Y/N, yes/no; C/EC/
UW/CU, Collins/Eurocollins/University Wisconsin/Custodiol; GN/TIN/
DM/PCKD/AS/T, glomerulonephritis/tubulointerstitial nephritis/diabetic
nephropathy/polycystic kidney disease/Alport syndrome/bilateral kidney
tumour; PRA, panel reactive antibody before transplantation; I/DGF/
NF, immediate/delayed/primary graft nonfunction; MP/ATG/anti-IL2R,
induction with methylprednisolon/anti-thymocyte globulin/anti-IL2-R
monoclonal antibody; CS, corticosteroids; AZA, azathioprine; MMF,
mycophenolate mofetil; STK, systolic blood pressure; IGT-DM,
impaired glucose tolerance (IGT) or diabetes mellitus in the post-trans-
plant period; BCS-T, Banff chronicity score-transfer; BSA, Banff score
of acute changes.
aCMV IgG, IgM P/N, human anti-CMV antibody detection by ELISA –
positive/negative.
bCsA-C0, trough level of cyclosporin A.
cCsA-C 2, 2-hour cyclosporin A post-dose level.
dFK-C0, trough level of tacrolimus.
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Figure 1 Banff chronicity score (BCS) of monitored groups and its
evolution during one year follow-up (NORMAL, normal histological
ﬁnding; S-TOX, subclinical toxicity of calcineurin inhibitors; M-TOX,
manifest toxicity of calcineurin inhibitors). Data are mean ± standard
deviation (SD) and level of statistical signiﬁcance P.
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groups of the S-TOX and M-TOX groups was inﬂu-
enced by the lower number of included patients and
differences in some of the parameters presented in
Table 4; the results therefore cannot be considered valid.
If, however, toxic signs were evaluated independently of
the graft function (S+M-TOX group), no difference in
respect of their inﬂuence upon the development of both
toxic and chronic changes expressed by the ﬁnal BCS
value was identiﬁed.
Discussion
In this prospective study, the incidence of subclinical tox-
icity in repeated protocol biopsies of transplanted kidneys
was monitored and we attempted to evaluate its impact
upon the progression of irreversible graft changes. Of the
total number of 158 biopsies conducted in the third week,
signs of toxic damage were seen in 20% of biopsy sam-
ples. More than 50% of these ﬁndings were clinically
silent, with normal serum creatinine levels. Only in 12%
of patients, possible toxicity as the cause of graft dysfunc-
tion was signalled by the concurrent detection of elevated
CI levels. Despite dose reduction, toxicity persisted in the
following biopsy in the third month and in the ﬁrst year
in more than 80% of patients in both S-TOX and
M-TOX study groups and 50% of these cases again
involved clinically silent ﬁndings. CI (C 0 and C 2) levels
in these groups did not differ signiﬁcantly and, similar to
the observations of Rush et al. [8], no signiﬁcant
difference was found in the comparison with the normal
histology group, either. The detection of toxicity in grafts
with normal and stabilized function thus depended upon
the performance of protocol biopsy.
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Figure 2 Serum creatinine of monitored groups and its evolution
during one year follow-up (NORMAL, normal histological ﬁnding; S-
TOX, subclinical toxicity of calcineurin inhibitors; M-TOX, manifest tox-
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(SD) and level of statistical signiﬁcance P.
Table 5. Comparison of Banff chronicity score of monitored groups in dependence on kind of used calcineurin inhibitor.
Group
3rd week 3rd month 1st year
CsA FK
b CsA FK CsA FK
NORMAL n (%) 18 (60.0) 12 (40.0) 12 (57.1) 9 (42.9) 8 (57.1) 6 (42.9)
CI-C0
a mean ± SD (lg/l) 281.3 ± 93.8 14.3 ± 3.4 202.3 ± 62.1 11.6 ± 7.5 167.6 ± 50.1 7.2 ± 1.5
BCS mean ± SD 0.72 ± 0.75 0.58 ± 0.79 0.58 ± 0.79 0.56 ± 0.73 1.13 ± 0.35 0.83 ± 0.75
PBCS 0.082 0.886 0.015
S-TOX n (%) 10 (58.8) 7 (41.2) 9 (64.3) 5 (35.7) 7 (58.3) 5 (41.7)
CI-C0 mean ± SD (lg/l) 277.0 ± 75.0 16.4 ± 6.0 194.3 ± 55.5 8.6 ± 3.9 179.4 ± 33.4 7.8 ± 2.5
BCS mean ± SD 0.60 ± 0.69 0.71 ± 0.76 1.22 ± 0.67 1.4 ± 0.55 1.57 ± 0.79 2.4 ± 0.55
PBCS 0.343 0.738 0.115
M-TOX n (%) 8 (50.0) 8 (50.0) 7 (53.8) 6 (46.2) 6 (54.5) 5 (45.5)
CI-C0 mean ± SD (lg/l) 296.9 ± 141.5 14.2 ± 2.4 176.3 ± 54.9 9.3 ± 1.9 153.0 ± 52.9 7.9 ± 1.3
BCS mean ± SD 0.50 ± 0.76 0.63 ± 0.52 1.57 ± 1.13 1.83 ± 0.75 1.83 ± 0.98 2.6 ± 0.55
PBCS 0.248 0.481 0.176
S+M-TOX n (%) 18 (54.5) 15 (45.5) 16 (59.3) 11 (40.7) 13 (56.5) 10 (43.5)
CI-C0 mean ± SD (lg/l) 285.8 ± 106.4 15.2 ± 4.4 186.4 ± 54.2 8.9 ± 2.8 167.2 ± 43.7 7.9 ± 1.9
BCS mean ± SD 0.56 ± 0.70 0.67 ± 0.62 1.38 ± 0.86 1.64 ± 0.67 1.69 ± 0.85 2.5 ± 0.53
PBCS 0.295 0.515 0.123
Data are mean ± standard deviation (SD) or number (%), and level of statistical signiﬁcance P.
NORMAL, normal histological ﬁnding; S-TOX, subclinical toxicity of calcineurin inhibitors; M-TOX, manifest toxicity of calcineurin inhibitors; S+M-
TOX, composite group with subclinical and manifest toxicity; BCS, Banff chronicity score; CsA, cyclosporin A.
aCI-C0, trough level of calcineurin inhibitor.
bFK, tacrolimus.
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opment in all of the study groups for the assessment of
pathogenic potential of these subclinical changes persist-
ing during the ﬁrst year after transplantation. A certain
shortcoming of our study has been the absence of
implantation biopsies which would provide more accurate
information on the scope of chronic changes to the donor
kidney. Yet we think that biopsies conducted in the third
week provided, in this respect, adequate predictive value.
As compliance with the histological sample adequacy
requirement and with the exclusion criteria has been
maintained, it was possible to consider the chronic
changes detected in the third week donor-associated. The
impact of other risk factors (Table 4), including cold
ischaemia time and the delayed graft function associated
therewith, was, in this short time horizon, rather theoreti-
cal. It was, however, taken into account in the same man-
ner as in the subsequent course of the study by
comparable activity in all of the studied groups. Impor-
tant for the evaluation of chronic changes development,
however, was the fact that the groups in the third week
did not signiﬁcantly differ in the level of baseline chronic
changes and hence their progression and graft function
alterations could be directly related to the presence of
toxicity. Our ﬁndings clearly show that not only toxicity
manifested by graft dysfunction but also its subclinical
form resulted, compared with normal histological ﬁnd-
ings, in a signiﬁcant progression of chronic changes as
early as in the third month after transplantation and this
trend was conﬁrmed by further signiﬁcant increases in
the BCS at the end of the one-year monitoring. Interest-
ingly, there was no signiﬁcant difference in the level of
chronic changes between the two toxicity groups in the
third month and in the ﬁrst year. A relatively pronounced
progression of chronic changes in this early post-trans-
plantation period corresponds to the ﬁndings of Chap-
man et al. [3], in whose set of protocol biopsies, the
maximum of chronic changes of grafts affected by ischae-
mia, acute rejection or toxicity was developing in a simi-
lar pattern over the ﬁrst 12 months after transplantation.
The degree of chronic changes at the end of one-year
monitoring, however, was not as pronounced in this
study population so as to be accompanied by signiﬁcant
impairment of the graft function. Nankivell et al. [5] also
observed an increase in serum creatinine in chronic neph-
rotoxicity only in a period exceeding one year from the
transplantation. Our evaluation of creatinine level devel-
opment in relation to subclinical toxicity and progression
of chronic graft changes has, moreover, been shown to be
questionable, as well as the creatinine response to CI dose
reduction. Despite repeated reduction, pronounced
growth of the BCS accompanied by a merely insigniﬁcant
increase in creatinine levels was seen in the S-TOX group.
In the M-TOX group, the signiﬁcant increase in the BCS
was accompanied even with an apparent – albeit statisti-
cally insigniﬁcant – decrease in creatinine levels, probably
because of the CI dose reduction. We therefore assume
that serum creatinine does not adequately reﬂect the
degree of graft damage especially in the early post-
transplantation period [3,9], and in our study population,
it was not possible to rely on changes in the glomerular
ﬁltration rate, either. This complies with the recommen-
dation to conduct protocol biopsies not only in patients
with high immunological risk to eliminate subclinical
rejection [2] but also for nonrejection indications, i.e. also
detection of toxicity [10], in particular during the ﬁrst
post-transplantation year. At present, it is not possible to
avail of any adequately sensitive and speciﬁc marker or
noninvasive procedure for the timely identiﬁcation and
further monitoring of toxicity [11,12]. The monitoring of
C 2 levels, which best correlate with the area under the
time-concentration curve (AUC), should reduce the risk
of toxicity, yet no adequate C 2 target value has been
established to date. In our study population, C 2 levels
ranging within the selected therapeutic limits did not pre-
vent the development of toxic changes, either. Moreover,
a pronounced ﬁbrogenic potential was demonstrated even
with the low target AUC in month 6 and year 1 after the
transplantation [13], which suggests that this approach
cannot eliminate inter-individual differences in sensitivity
to CI, probably genetically induced [14,15].
To date, the study population has been evaluated only
for the impact of persisting toxicity upon the develop-
ment of chronic histological changes over the period of
one year. Nevertheless, with the signiﬁcant increase in the
BCS as early as in the third month after transplantation,
we consider this period suitable in many cases for the
adjustment of immunosuppressive therapy. The repeated
CI dose reduction in our study population had only a
disputable effect associated with more than 80% of per-
sisting toxic changes in the following biopsy. Further-
more, in almost 15% of patients, it was accompanied by
some form of acute rejection and further dose reduction,
particularly in patients with CI levels at the bottom part
of the therapeutic range, could further increase this per-
centage. The comparisons of cyclosporin A and tacroli-
mus have shown that independent of the graft function,
their toxicity was similar and had comparable impact
upon the progression of chronic changes in the course of
the one-year monitoring. The outcomes of our study are
consistent with the ﬁndings of other authors who have
documented a similar impact of both CI upon the devel-
opment of histological toxic changes [5] as well as upon
the degree of chronic interstitial changes and level of graft
function at the end of the ﬁrst year after transplantation
[13]. Taking this into account, a conversion to an
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more efﬁcient process could be – even in the case of sub-
clinical toxicity – a conversion to any of the mTOR
inhibitors, sirolimus or everolimus.
The easiest strategy resulting in the elimination of CI
nephrotoxicity is, however, a complete elimination of this
group from immunosuppressive protocols [16]. Positive
outcomes in this respect have been presented by a com-
parative study documenting excellent one-year graft sur-
vival in low-risk patients with transplants from living
donors, treated primarily with tacrolimus or sirolimus
[17]. The safety of application of these recommendations
in high-risk kidney transplant recipients, however,
requires prior assessment in controlled studies. Also, until
the positive effects of sirolimus or everolimus on long-
term graft survival are conﬁrmed, we believe, consistent
with other authors, that CI will remain the cornerstone of
immunosuppressive protocols [13] and that their admin-
istration requires optimization [18]. On the basis of study
outcomes, we are, however, in favour of the option to
exclude CI from therapy at the end of the third month
after transplantation [19,20] by means of conversion to
mTOR inhibitors in patients with repeatedly detected tox-
icity, low immunological risk, low baseline proteinuria
[21] and negative history and current exclusion of acute
rejection changes. Where these conditions are met, and
regardless of the graft function and previous incidence of
rejection, conversion should be probably always carried
out, if toxicity persists in the ﬁrst year after transplanta-
tion (Table 6). As in addition to preventing further pro-
gression of chronic damage, disappearance of the CI
haemodynamic effect may be expected in this period as
well as the remodelling of previously developed altera-
tions and, in dysfunctional grafts, also function improve-
ment [22]. In case of mTOR inhibitors contraindication
is present, further CI dose reduction should be considered
and conversion to tacrolimus performed, achieving con-
centrations close to the lower therapeutic range. Although
our results suggest that tacrolimus has the same toxic
potential as cyclosporin A, its more favourable metabolic
proﬁle and better anti-rejection activity may be made use
of in the long-term.
It is necessary to state that data evidencing the impact
of subclinical toxicity upon the progression of chronic
changes, supported by a comparison with ﬁndings from
protocol biopsies in patients with normal histological
results and clinically manifest toxicity, have not been
published to date. Application of these ﬁndings could be
of importance particularly at those workplaces where
sequential biopsies of transplanted kidneys are not part of
routine observational post-transplantation protocols.
Sequential biopsies represent the only feasible tool allow-
ing to detect subclinical toxicity and to control its persis-
tence. On the other hand, it is an invasive procedure,
presenting certain risks to the patient. In our set of 424
protocol biopsies in total, it was not necessary to perform
any graftectomy or any surgical intervention because of
haemorrhagic complications. Other serious complications
have occurred only in three cases (0.7%), where two
patients were given two therapeutic units of erythromass
for a larger scope perirenal haematoma, one patient had
to undergo superselective embolization of progressing
arteriovenous parenchymal ﬁstula with a risk of rupture.
Minor complications, i.e. development of a small perire-
nal haematoma, transient macroscopic haematuria and
minor arteriovenous ﬁstula were reported in 27 cases
(6.4%), without any further negative impact upon the
patient and the fate of transplanted kidney. The incidence
of clinically signiﬁcant complications was hence low in
our workplace and comparable to data presented in simi-
lar studies. In our opinion, the protocol which we have
presented, currently supplemented with a routine conduct
of implantation biopsies, seems to be adequate for the
period of the ﬁrst post-transplantation year in terms of
the number of sequential biopsies. Our workplace avails
of it with much beneﬁt not only for the detection of toxic
changes but also for the control of rejection complica-
tions arising in association with repeated reduction and
minimization of CI doses or their complete elimination.
It is relatively considerate to the patient and to-date preli-
minary results from two-year and three-year biopsies sug-
gest that it provides sufﬁcient space for an effective
adjustment of the immunosuppressive therapy.
In conclusion, subclinical toxicity in the ﬁrst year after
transplantation affects a percentage of grafts comparable
to that of its clinically manifest form associated with renal
dysfunction. It occurs independently of dosage, blood
level and type of applied CI. Even when the dose is
reduced, it persists in repeated biopsies in a high percent-
age and results in signiﬁcant progression of chronic
changes as early as in the course of the ﬁrst year after
transplantation and hence represents an independent risk
factor for chronic graft damage. Protocol biopsies seem to
be a good tool for the detection of subclinical toxicity
and for the control of its persistence. The impact of sub-
clinical toxicity upon long-term graft survival, the indif-
ferent effects of both CI and the safety of their
elimination particularly in grafts with normal function,
will require veriﬁcation in a larger population and over a
longer time span.
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